Have you seen this:
https://www.drugs.com/compare/apixaban-vs-pradaxa
On the face of it, just this one site mind you, prodaxa is somewhat more highly rated by users than is apixaban, but I'm not sure what to make of that. It could be that it was a sales pitch. People learn they need a DOAC, they've heard of Eliquis and rivaroxaban, and of their caveats, and the cardiologist says, 'We have a new one that people like,' and instantly that becomes the one they want to use. A placebo effect kicks in, they don't have any problems, and so they go to a site and rate it highly. That's what I think happens. It might also be less costly.

Note that the two compounds do not act on the same principles of clotting. In fact, patients are advised not to use aspirin because it doesn't do as good a job as Eliquis, and it also acts as a pro-thrombin inhibitor, like prodaxa.

Eliquis has an excellent record so far of reducing the risk of stroke for AF/flutter sufferers by two thirds or thereabouts. I don't know where you will find any meaningful stats about prodaxa. Some sleuthing might be in order.